Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Ther. 2014 May;22(5):1056-62. doi: 10.1038/mt.2014.21. Epub 2014 Feb 20.

Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Author information

1
Department of Surgery, Division of Neurosurgery, University of Alabama, Birmingham, Birmingham, Alabama, USA.
2
Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
3
Department of Neurosurgery, Cedars-Sinai, West Hollywood, California, USA.
4
Oncolytics Biotech, Calgary, Alberta, Canada.

Abstract

Reovirus, an oncolytic RNA virus exhibiting antiglioma activity, was shown in a previous single institution phase 1 study found that the inoculation of the virus to be well tolerated in patients with recurrent malignant glioma (MG). The goals of multicenter study reported herein were to determine the dose-limiting toxicity, maximum tolerated dose, and target lesion response rate when reovirus was administered in a novel fashion via intratumoral infusion for 72 hours in patients with recurrent malignant glioma. Fifteen adult patients were treated in a dose escalation study ranging from 1 × 10(8) to 1 × 10(10) tissue culture infectious dose 50, tentimes the dose achieved in the previous trial. Neurological, functional examinations, and imaging studies were completed pre- and postinfusion. There was one grade 3 adverse event (convulsions) felt to be possibly related to treatment, but no grade 4 adverse events considered probably or definitely related to treatment. Dose-limiting toxicity were not identified and a maximum tolerated dose was not reached. Evidence of antiglioma activity was seen in some patients. This first report of intratumoral infusion of reovirus in patients with recurrent malignant glioma demonstrated the approach to be safe and well tolerated, warranting further studies.

PMID:
24553100
PMCID:
PMC4015229
DOI:
10.1038/mt.2014.21
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center